NKR 2

Drug Profile

NKR 2

Alternative Names: CAR NKG2D; CAR-T NKR-2; CM-CS-1; NKR 2 T-cell; NKR-2; NKR-2 T-cell immunotherapy; NKR-T cells

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator Dartmouth College
  • Developer Celyad; Dana-Farber Cancer Institute
  • Class Antineoplastics; CAR-T cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Angiogenesis inhibitors; Cytotoxic T lymphocyte stimulants; Immunostimulants; NK cell lectin-like receptor subfamily K modulators; Regulatory T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 08 Mar 2017 Th US FDA approves IND application for the phase I/II THINK trial for Solid tumours
  • 16 Feb 2017 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Belgium (IV)
  • 16 Feb 2017 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top